Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML (NCT06580106)
A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Who can join: Review the eligibility criteria below.
Location: Levine Cancer Institute — Charlotte, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
- Biospecimen samples (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Levine Cancer Institute — Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (980) 292-0817
Email: courtney.schepel@advocatehealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Leukemia, Myeloid, Acute
- A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Gilbert, Arizona
- Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia — Duarte, California
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy — Duarte, California
- A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — Birmingham, Alabama
- A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — Calgary, Alberta
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — Houston, Texas
Explore by condition: All Leukemia, Myeloid, Acute clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.